Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CETP Trials Still Inhibited As Torcetrapib Results Fail To Illuminate Outcomes

Executive Summary

The much anticipated results from Pfizer's failed torcetrapib trials did little to illuminate the cause of adverse outcomes in cholesteryl ester transfer protein inhibition, leaving an expectant industry with a charge to start more clinical trials

You may also be interested in...



Dr. Reddy's To Close Atlanta Facility In Reorganization; Focus On Key Markets To Drive Revenues To $3 Billion By 2013

MUMBAI - Need for optimization of infrastructure and resources, falling productivity and spiraling cost of discovery research has led Dr. Reddy's Labs, one of India's largest drug companies, to integrate its drug discovery operations with Aurigene - a partnership-based discovery biotech unit that it owns in Bangalore

Esperion, Again: Pfizer's First Spin-Out's Familiar Look

This examination of Pfizer's first foray into spin-outs is a sidebar to "Can Out-Partnering Power Pfizer Over the "Second Cliff?"" Pfizer's Esperion spin-out hopes to pick up where it left off five years ago when Pfizer bought its first incarnation: developing HDL-raising therapies for CV disease.

Merck Hopes To Make A Success Story of CETP Inhibitors And Obesity Drugs

Merck is hoping to find success where other firms have failed: its late stage pipeline includes two programs in drug classes where the lead candidates from other companies have not managed to gain approval

Related Content

UsernamePublicRestriction

Register

PS048990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel